See more : OCI Company Ltd. (010060.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Enliven Therapeutics, Inc. (ELVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enliven Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bit Brother Limited (BETSF) Income Statement Analysis – Financial Results
- Pantaflix AG (PAL.DE) Income Statement Analysis – Financial Results
- Micromobility.com Inc. (MCOM) Income Statement Analysis – Financial Results
- BYD Company Limited (BYDDF) Income Statement Analysis – Financial Results
- Redington Limited (REDINGTON.NS) Income Statement Analysis – Financial Results
Enliven Therapeutics, Inc. (ELVN)
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 297.00K | 622.00K | 99.00K | 97.00K | 33.00K | 0.00 | 0.00 |
| Gross Profit | -297.00K | -622.00K | -99.00K | -97.00K | -33.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 64.57M | 31.02M | 20.47M | 8.24M | 19.01M | 8.24M | 7.92M |
| General & Administrative | 18.96M | 7.77M | 4.29M | 1.08M | 5.11M | 2.44M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -33.00K | 0.00 | 0.00 |
| SG&A | 18.96M | 7.77M | 4.29M | 1.08M | 5.07M | 2.44M | 987.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -9.68M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 83.53M | 38.79M | 24.76M | 9.32M | 24.08M | 10.68M | 8.91M |
| Cost & Expenses | 83.53M | 38.79M | 24.76M | 9.32M | 24.12M | 10.68M | 8.91M |
| Interest Income | 11.97M | 1.13M | 22.00K | 31.00K | 578.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 297.00K | 215.00K | 115.00K | 97.00K | 33.00K | -660.00K | 0.00 |
| EBITDA | -81.93M | -38.58M | -24.65M | -9.27M | -23.43M | -11.34M | 221.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -83.53M | -38.79M | -24.76M | -9.32M | -24.12M | -10.68M | -8.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 11.95M | 1.13M | 22.00K | -9.65M | 653.00K | -660.00K | 9.13M |
| Income Before Tax | -71.58M | -37.66M | -24.74M | -18.97M | -23.46M | -11.34M | 221.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 88.00K | -22.00K | -31.00K | 653.00K | -821.14K | 221.00K |
| Net Income | -71.58M | -37.75M | -24.72M | -18.94M | -23.46M | -11.34M | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.01 | -6.03 | -3.17 | -14.14 | -5.43 | -2.62 | 0.00 |
| EPS Diluted | -2.01 | -6.03 | -3.17 | -14.14 | -5.43 | -2.62 | 0.00 |
| Weighted Avg Shares Out | 35.55M | 6.25M | 7.81M | 3.48M | 4.32M | 4.32M | 4.32M |
| Weighted Avg Shares Out (Dil) | 35.55M | 6.25M | 7.81M | 3.48M | 4.32M | 4.32M | 4.32M |
10 Top Penny Stocks With Unusual Options Activity This Week
Penny stocks to watch today with unusual options action. The post 10 Top Penny Stocks With Unusual Options Activity This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Looking for Popular Penny Stocks to Buy? 3 to Watch Now
Which penny stocks are you buying today? The post Looking for Popular Penny Stocks to Buy?
5 Top Penny Stocks With Unusual Options Activity Today
Penny stocks to watch with unusual options activity today. The post 5 Top Penny Stocks With Unusual Options Activity Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
What Makes IMARA Inc. (IMRA) a New Buy Stock
IMARA Inc. (IMRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read Why Imara Shares Are Falling Today
Imara Inc (NASDAQ: IMRA) shares are falling after interim analyses of its Ardent Phase 2b trial of tovinontrine (IMR-687) in sickle cell disease (SCD) and Forte Phase 2b trial in beta-thalassemia. Data from the sickle cell disease study interim analysis demonstrated that.
Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript
Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript
7 Biotech Stocks With Key Catalysts in March
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. The post 7 Biotech Stocks With Key Catalysts in March appeared first on InvestorPlace.
Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that the company will...
Best Penny Stocks To Buy? 3 To Watch With Insider Buying In February
Insiders are scooping up these penny stocks in February. The post Best Penny Stocks To Buy?
Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that Rahul Ballal, Ph.D.,...
Source: https://incomestatements.info
Category: Stock Reports